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Aim: Minocycline has neuroprotective activities in several models of neurological disorders 
including spinal cord injury (SCI) where it prevents axonal loss and improves functional 
recovery. There are still gaps of knowledge on minocycline in SCI including whether 
it ameliorates neuronal loss at the focal site of trauma, and whether minocycline reduces 
the activity of matrix metalloproteinases (MMPs), a family of enzymes implicated in the 
pathophysiology of SCI. This study addressed these gaps. Methods: Mice were treated with 
either minocycline or vehicle control after a spinal cord contusion. MMPs were compared 
between the two groups using real time polymerase chain reaction and zymography. 
Immunohistochemistry was used to examine microglial activation and neuronal cell death. 
Results: While several MMP members were elevated in the spinal cord following injury, 
treatment with minocycline did not affect their expression. Importantly, minocycline reduced 
the loss of neurons in the epicenter of damage to the spinal cord and in segments caudal and 
rostral to the injury. Conclusion: Despite the inability of minocycline to alter MMPs, the 
results of neuroprotection at the lesion site support the continued testing of minocycline as a 
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INTRODUCTION
Minocycline, a synthetic derivative of tetracycline, 
has been used for the treatment of acne for several 
decades.It has been proposed as a promising 
neuroprotective agent in multiple central nervous 
system (CNS) patho log ies inc luding st roke, 
Huntington’s disease, amyotrophic lateral sclerosis 
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and multiple sclerosis [1-3]. Minocycline has also 
been demonstrated to have beneficial effects in 
the treatment of acute spinal cord injury (SCI), a 
condition for which therapeutic treatments are urgently 
needed. Indeed, a phase 2 clinical trial administering 
minocycline in acute human spinal cord injury was 
completed in Canada with promising early results[4]
and a phase 3 clinical trial is ongoing (ClinicalTrials.
gov Identifier: NCT01828203). Encouragingly, the 
efficacy of minocycline in reducing tissue damage and 
in ameliorating functional impairment in SCI has been 
demonstrated despite variations in the models used, 
the species tested and the treatment paradigm[5-7]. 
The mechanism of  ac t ion of  minocyc l ine in 
neurological diseases appears not to be related to its 
antimicrobial activity, but rather to immunomodulation, 
blockade of excitotoxicity and inhibition of cell death 
pathways[1,2,5-7], all of which have been implicated in 
the pathophysiology of SCI. 
Minocycline has also been reported to inhibit the 
production and activity[8-10] of a family of proteolytic 
enzymes known as the matrix metalloproteinases 
(MMPs). A large number of MMPs have been identified 
and, collectively, the MMPs are capable of degrading 
all components of the extracellular matrix (ECM). As 
such, MMPs have roles in several developmental 
processes that involve ECM turnover as well as in 
wound healing throughout life. However, the aberrant 
expression of these molecules is detrimental to several 
diseases of the CNS, including SCI [11]. We have 
previously shown that several MMPs were upregulated 
after SCI in mice; in particular, we provided evidence 
that MMP-12 expression after SCI was linked to 
increased blood spinal barrier permeability, microglial 
activation, macrophage infiltration, and worsened 
functional outcome following injury[12]. In addition, 
Hsu et al.[13] and Noble et al.[14] demonstrated that 
MMP-9 limited functional recovery in the short-term 
following SCI in rats, although MMP-2 had an opposite 
outcome 7-14 days after injury.
Given that minocycline is currently in a phase 3 
trial in traumatic SCI (ClinicalTrials.gov Identifier: 
NCT01828203), it is important to have a comprehensive 
picture of its spectrum of activity. Thus, in this 
study, we determined whether or not the efficacy of 
minocycline in SCI was due in part to its ability to 
inhibit the expression or activity of MMPs. In addition, 
we examined the response of microglia/macrophages 
following SCI and the impact of minocycline treatment. 
Finally, we addressed whether minocycline could 
protect against the death of neurons at the site of 
traumatic impact itself, since previous work has 
examined axons of passage and higher order neurons 
that project through the spinal cord[5]. These studies 
are relevant to the potential application of minocycline 
as a neuroprotective agent after SCI.
METHODS
Surgery and minocycline treatment
CD1 outbred mice were anesthetized, the spinal cord 
exposed, and extradural mechanical compression of 
the cord with a modified aneurysm clip was achieved 
as previously described[5]. In brief, surgery consisted of 
anesthetizing mice with a mixture of ketamine/xylazine 
(200 and 10 mg/kg, respectively) intraperitoneally. 
Animals were subsequent ly immobi l ized in a 
stereotactic frame. An incision was made in the skin 
and the muscle and tissue overlying the vertebral 
column were blunt dissected away. Using the spiny 
process of T2 as a landmark, a laminectomy was 
performed at the level of T3/T4 and the spinal cord 
was exposed. A rigid hook was used to clear a path 
underneath the cord so that a modified aneurysm clip 
with a closing force of 8 g could be applied. Extradural 
compression of the cord was achieved by allowing the 
clip to slam shut on the cord producing mechanical 
trauma. The clip was maintained in position for one 
minute producing damage that also had ischemic 
components. Following injury the clip was removed 
and the wound was closed using nylon suture. Mice 
recovered in a room maintained at 27 ºC where they 
were kept thereafter for the determined survival time. 
Manual expression of the bladder was required twice 
daily and the food and water were placed directly in 
the cage to allow ready access.
One hour after surgery, mice were randomized and 
injected intraperitoneally with either a solution of 
minocycline at a dose of 50 mg/kg or saline vehicle 
control. Subsequent injections were given at 24-h 
intervals until sacrifice. Following the second injection 
of 50 mg/kg, the dose of minocycline was reduced 
to 25 mg/kg for all remaining treatments. This dose 
regimen is identical to that used in our previous study[5] 
that demonstrated behavioral recovery by 3 days post-
injury in the minocycline compared to vehicle group. 
Analyses of MMPs
TaqMan real time PCR was used to profile MMP 
mRNA levels as detailed[15]. Minocycline and vehicle 
treated mice were sacrificed 1, 2 and 5 days after 
injury (4/group) and 4 mice served as uninjured 
controls. Spinal cords were removed and a 1-cm 
segment including the injury site was homogenized 
in Trizol reagent and total RNA extracted. One 
microgram of RNA was reverse transcribed to make 
cDNA. Each PCR reaction contained the equivalent 
               Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ November 28, 2017
Rice et al.                                                                                                                                                                                    Minocycline in spinal cord injury
245
of 5 ng of reverse transcribed RNA. The 18S rRNA 
gene was used as an endogenous internal control to 
account for differences in the extraction of original 
tissue and reverse transcription of total RNA. Primer 
sequences for the TaqMan assays were previously 
described elsewhere[15], and statistical validity for the 
multiple TaqMan targets has been corroborated.
Gelatin zymography of one cm segments of spinal 
cord was described previously[16] as was the method 
of in situ zymography[17]. Note that while gelatin 
zymography is a technique reliant on the activity of 
MMP-2 and -9 to degrade gelatin in-gel, it is ultimately 
proportional to, and thus a reflection of, the amount of 
MMP-2 and -9 in the test samples.
While the above in-gel gelatin zymography is a 
manifestation of protein content, the net gelatinolytic 
activity (i.e. overall enzyme activity in a milieu that 
also contains enzyme inhibitors) in an intact non-
fixed tissue specimen can be evaluated using in situ 
zymography. For this method spinal cord injury was 
induced in 14 mice; 7 animals were injected with 50 
mg/kg of minocycline 1 h and 24 h after, while the other 
7 received saline vehicle at the same time points. One 
hour after the second injection, mice were given an 
overdose of ketamine/xylazine intraperitoneally and the 
spinal cord was carefully removed and directly frozen 
in isopentane at -70 ºC. Twenty µm thick longitudinal 
sections were cut on a cryostat, mounted on glass 
slides and stored at -80 ºC. Sections were thawed and 
incubated in a humid chamber in 100 mL (50 µL/s) of 
reaction buffer containing 100 mg/mL of FITC-labeled 
dye-quenched-gelatin (EnzCheck collagenase kit, 
Molecular probes, Eugene, OR) for 3 h at 37 ºC[16,17]. 
At the end of the incubation period slides were rinsed 
in PBS, fixed and then mounted. Prepared slides were 
observed using fluorescence microscopy. Sections 
incubated without dye-quenched-gelatin did not 
exhibit fluorescence and served as negative controls. 
Samples from SCI animals were analyzed in a blinded 
manner using a qualitative rating scale from 0 to 4, with 
zero representing no fluorescence and a score of 4 
depicting maximal in situ zymography signal.
Immunohistochemistry
Spinal cord compression was performed in 36 mice 
as described above. Mice were randomly treated with 
either minocycline or vehicle and survived for 2 or 5 
days (n = 9/group). Animals were given an overdose of 
ketamine/xylazine and the spinal cords were excised 
and post-f ixed in 10% neutral buffered formalin 
and subsequently embedded in paraffin wax. Six 
micrometer thick sections were cut on a microtome 
and collected at a frequency of 1:10. Three series 
were obtained for immunohistochemical analysis 
of microglia, neurons and apoptotic cells using the 
antibodies Iba1, NeuN (Chemicon) and the Apoptag® 
Fluorescein In Situ Apoptosis Detection Kit (Tunel, 
Chemicon). lba1 and NeuN immunolabeling to detect 
microglia and neurons, respectively, was performed as 
previously described[12]. For NeuN labeling, sections 
had to undergo antigen retrieval by boiling in 10 mmol/L 
sodium citrate buffer (pH 6.5) for 10 min. Slides were 
incubated with mouse anti-NeuN (1:50, Chemicon) 
overnight at 4 ºC. Biotinylated anti-rabbit IgG was used 
for the secondary antibody and staining was visualized 
with ABC using DAB as the substrate.
For blinded Iba1 analyses, the degree of microglial/
macrophage activation was determined by examining 
the morphology and density of the Iba1 labeled 
cells. Considerations were made for the size, shape 
and relative density of Iba1 labeled cells. Briefly, 
Iba1-stained sections were scored for microglial/
macrophage activation using a scale from 0-4 where 
0 was normal cord and 4 was the presence of highly 
activated microglia/macrophages. For NeuN labeled 
tissue, longitudinal sections containing central canal 
were identified as well as sections about 180 µm away 
on either side of the center section (total of 3 sections/
mouse). The number of positively stained cells was 
manually counted from 5 regions of each section 
corresponding to lesion area, +1 mm rostral, +2 mm 
rostral, +1 mm caudal and +2 mm caudal. Unbiased 
stereology was not used in the blinded counts. Data 
were analyzed using univariate analysis of variance 
with scheffe post-hoc comparisons. Similarly, for Tunel 
labeled tissue, the total number of labeled cells in a 
1-cm segment of cord, from a section containing 
central canal and including the lesion epicenter, 
was counted. In this case, data was analyzed using 
unpaired t-tests at 2 and 5 days.
RESULTS
Expression profile of MMP transcripts in 
minocycline and vehicle treated SCI animals
The expression profile of 20 MMPs was examined by 
TaqMan PCR in mouse spinal cord following injury. 
Figure 1 shows that transcripts encoding MMP-3, -7, 
-10, -11, -12, -13, -19, -20 and -21 were elevated after 
spinal cord injury compared to uninjured controls, 
while those of MMP-23 and -24 were reduced. 
Compared to vehicle treated SCI samples, minocycline 
administration had no significant effect on altering the 
MMP transcripts at 1, 2 and 5 days after injury. 
We also measured transcripts encoding physiological 
antagonists of MMPs, the 4 tissue inhibitors of 
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Figure 1: No impact of minocycline treatment on the profile of MMPs after SCI. While the expression of several MMPs was altered after 
SCI, none of these MMPs were significantly different between the vehicle and minocycline groups. Values are mean ± SEM of 4 samples 
from vehicle (V) or minocycline (M) group, at 1, 2 or 5 days after injury. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to naïve controls. 
All analyses were by one-way ANOVA with Tukey’s multiple comparisons. MMPs: matrix metalloproteinases; SCI: spinal cord injury
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metalloproteinases (TIMPs). Figure 2 shows that the 
expression of TIMP-1, but not TIMP-2, -3 and -4, was 
upregulated by injury. The levels of all four TIMPs 
in the minocycline treated cords were not altered 
from those of the vehicle treatment groups, with the 
exception of TIMP-4 that was raised by minocycline at 
1 day of injury.
Gelatin zymography shows that minocycline 
does not alter MMP-2 and -9 protein content
Measurement of transcripts encoding MMPs provides 
a broad overview of the changes occurring to all 
known MMP members, since several individual MMPs 
continue to be difficult to measure using Western blot 
or activity assays. A reproducible and commonly used 
method for protein levels involves the determination 
of MMP-2 and MMP-9 by the method of gelatin 
zymography. Although we did not detect the elevation 
of their transcripts after SCI [Figure 1], MMP-9 
protein can be made outside of the CNS, including in 
neutrophils, and then deposited into the lesion site. For 
these reasons, we examined the levels of MMP-2 and 
-9 protein using gelatin zymography. The pro-MMP-9 
protein was minimally expressed in control uninjured 
spinal cord tissue [Figure 3A]. Injury resulted in an 
upregulation of both the pro- and active forms of MMP-
9 one day after injury. Minocycline treatment had no 
obvious effect on the injury-induced MMP-9. The pro-
MMP-2 species did not elevate profoundly after injury 
or in the presence of minocycline. The quantification of 
the gelatin zymograms is displayed in Figure 3B and 
confirms the lack of effect of minocycline on MMP-2 
and -9 protein expression after SCI.
In situ zymography reveals no alterations of 
net proteolytic activity by minocycline
Although gelatin zymography [Figure 3A] is based on 
the degradation of gelatin in-gel by MMP-2 and -9, 
it is a reflection of the content of these gelatinases 
(MMP-2 or -9) rather than their net enzymatic activity, 
given that all enzyme co-factors are supplied in 
optimal amounts for manifestation of catalysis in-gel. 
In addition, while the mRNA for MMPs are elevated 
in SCI [Figure 1], so are the transcripts for the TIMP 
inhibitors [Figure 2], thus making it relevant to address 
the balance of proteolytic activity in specimens. 
To determine the net proteolytic activity existent 
in the injured cord, in situ zymography was used, 
whereby the gelatin-FITC substrate was overlaid onto 
longitudinal unfixed sections encompassing the injured 
area [17], and where if there is relative abundance 
of enzyme over inhibitors, then there would be net 
proteolysis of the gelatin-FITC. In normal uninjured 
cord, no fluorescence signal was evident. Twenty-
four hours following SCI, varying grades of signals 
were observed [Figure 3C]. Blinded analyses across 
14 injured specimens concluded that there was no 
Figure 2: TIMPs remain largely unaltered by minocycline treatment after SCI. TIMP-1 was the only inhibitor that was altered (upregulated)
by injury compared to naïve controls, and there was no effect of minocycline treatment with the exception of an increase of TIMP-4 at 1 
day after SCI. Values are mean ± SEM of 4 samples from vehicle (V) or minocycline (M) group, at 1, 2 or 5 days after injury. *P < 0.05, 
**P < 0.01 and ***P < 0.001 compared to naïve controls (one-way ANOVA with Tukey’s multiple comparisons). TIMPs: tissue inhibitors of 
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difference in net proteolysis around the lesion site 
between vehicle and minocycline samples (1.6 ± 0.3 
and 2.0 ± 0.5 graded scores, respectively) (mean ± 
SEM, P > 0.05, Mann-Whitney non-parametric test).
Minocycline reduces microglial reactivity at 
the site of injury
Iba1 immunoreactivity was performed on spinal 
cord sections to assess the degree of microglial/
macrophage reactivity. Figure 4 displays Iba1 labeling 
in the spinal cord of normal uninjured mice (A, B), or 
in vehicle (C, D) or minocycline treated (E, F) mice 
after SCI. The Iba1 antibody does not discriminate 
between microglia and macrophages, so positive cells 
are collectively referred to as microglia/macrophages. 
The density of Iba1 positive cells adjacent to the 
epicenter of injury was prominently increased after 
SCI (C, D) compared to normal uninjured conditions, 
and this appeared qualitatively to be reduced in the 
minocycline treated samples (E, F). Furthermore, 
the morphology of microglia/macrophages in vehicle 
treated mice (D) was indicative of highly activated 
cells with amoeboid morphology and thick stubby 
processes, contrasting the highly ramified morphology 
of microglia in the normal cord [Figure 4B]. In contrast, 
minocycline treated mice had microglia/macrophage 
morphology that was intermediate between these 
extremes (F). As the morphological transformation 
Figure 3: Increased protein levels of MMP-9 after SCI are unaltered by treatment with minocycline. A: Gelatin zymogram displaying pro-
MMP-2 and -9 protein species (designated in figure by MMP-2 and MMP-9, respectively) in spinal cords from uninjured control mice; after 
injury, additional bands running between pro-MMP-2 and pro-MMP-9 represent the activated forms of MMP-9. Minocycline treatment did not 
markedly change the expression pattern of MMP-2 or -9 levels after SCI (A) and this was corroborated by quantification of band densities 
through densitometry (n = 6 each) from the zymogram (B); C: in situ zymography of a longitudinal section from non-injured (left, slide has 
been over-exposed to confirm the lack of signal) or vehicle-treated mouse (right, 2 days after injury). In situ zymography signal at the lesion 
site (one longitudinal section containing the central canal per mouse, n = 7 per group) is not different between vehicle- and minocycline-
treated mice in blinded analyses (see text). MMPs: matrix metalloproteinases; SCI: spinal cord injury
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of microglia from ramified to amoeboid forms is 
indicative of their increasing state of activation, these 
results suggest that minocycline reduced microglia/
macrophage activation after injury.
We also determined the representation of microglia/
macrophages at the epicenter of injury. We found 
that the density of Iba1 labeled cells was qualitatively 
lower in minocycline treated mice (H) than in vehicle 
controls (G), even though the morphology of cells, 
with the majority being amoeboid, did not dif fer 
between the 2 groups. To quantitate the extent of 
microglial/macrophage reactivity encompassing 
the lesion and remote areas, Iba1 immunoreactivity 
was scored by three independent observers blinded 
to treatment according to previously published 
methods[12]. Agreement between observers was good 
in large part and the identical result of 2 reviewers 
was noted as the score for a particular section. The 
blinded assessments [Figure 4I] indicated that there 
was a significant difference in Iba1 immunoreactivity 
between minocycline and vehicle treated mice 5 days 
after injury (P < 0.05, Mann Whitney U test).
Minocycline decreases apoptotic cell death as 
revealed by Tunel labeling
The number of Tunel positive cells was counted in 
sections of spinal cords taken from mice at 2 and 5 
days after injury. The data shows cell death occurring 
at 2 and 5 days,and that minocycline treatment 
reduced the number of Tunel positive cells at the latter 
time point [Figure 5]. We did not address whether the 
Tunel positive cells were oligodendrocytes and/or 
neurons, and whether there is preferential rescue of 
one cell type versus another by minocycline. 
Minocycline spares neurons at the lesion site 
after spinal cord injury
Figure 6 displays NeuN labeling in the normal 
uninjured spinal cord (A, B), in vehicle treated cord at 
5 days after injury (C, D), and in minocycline treated 
mice at comparable points (E, F). While neurons were 
lost after SCI, there appears to be more neurons 
preserved in the minocycline versus the vehicle group. 
To confirm this, blinded counts were taken from the 
lesion epicenter and areas both rostral and caudal to 
the injury site. Univariate analysis of variance revealed 
that there was a significant area effect at 2 and 5 days 
(P < 0.001 for both), where SCI resulted in reduced 
neuron numbers, with the greatest loss occurring at 
the lesion site and with more spared neurons as the 
distance from the epicenter increased rostrally and 
caudally (lesion site significantly different from areas 1 
and 2 mm rostral and caudal from the lesion epicenter, 
P < 0.001) [Figure 6]. Furthermore, while the same 
pattern of loss was present in minocycline treated 
animals, there was greater preservation of neurons 
after SCI when compared to vehicle controls (P < 0.001 
Figure 4: Microglial/macrophage activation and infiltration is 
reduced in minocycline treated mice. Microglia/macrophages 
were visualized using Iba1 immunostaining 5 days after injury. A 
comparison of representative sections from normal uninjured mice 
(A, B) and SCI mice treated with vehicle (C, D) reveals that there 
was increased density of cells in the SCI tissue, as well as a more 
amoeboid morphology characteristic of microglial/macrophage 
activation after SCI (D). In contrast, in minocycline treated mice 
(E, F), the density of microglia/macrophages appeared to be 
qualitatively reduced compared to vehicle controls. In minocycline 
treated mice (F), the microglia, while demonstrating morphological 
changes indicative of activation (i.e. shortened and thickened 
processes), did not progress as much as in the vehicle animals (D). 
Finally, within the epicenter of the injury in vehicle and minocycline 
treated animals (G and H respectively), there was an increased 
number of Iba1 labeled cells displaying an amoeboid morphology, 
with a greater density of these cells in the vehicle treated mice 
compared to the minocycline group. Iba1 stained sections were 
scored blinded for microglial/macrophage activation using a scale 
from 0-4, where 0 was normal cord and 4 indicated the presence 
of highly activated microglia/macrophages. There was a significant 
difference (*P < 0.05, Mann Whitney U test) in the morphology 
and density of Iba1 labeled cells in minocycline treated mice after 
SCI compared to vehicle (I, where each point represents one 
longitudinal section containing the central canal per mouse). SCI: 
spinal cord injury
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for both 2 and 5 days) [Figure 6].
DISCUSSION
MMPs are implicated in neural cell death. The 
application of MMP-1 and -9 to neurons in culture 
results in their demise[17]. In animal models of SCI, 
MMP-12 transcripts were upregulated 189 fold over 
basal levels, and functional recovery was significantly 
improved in MMP-12 null mice compared to wild-type 
controls[12]. Similarly, a role for MMP-9 in SCI was 
demonstrated in a study by Noble et al.[14] who showed 
that MMP-9 was upregulated following a contusion 
injury and that this was correlated with a reduction in 
blood spinal barrier integrity and the recruitment of 
inflammatory neutrophils. These authors also showed 
that functional recovery from SCI was significantly 
improved in MMP-9 null mice compared to wild-type 
controls. In correspondence with these results, inhibitors 
of MMPs applied acutely following SCI improved 
histological and functional outcomes[14]. Nonetheless, it 
must be borne in mind that MMPs also have beneficial 
functions in the CNS, and that the prolonged usage of 
MMP inhibitors can impair recovery[18,19].
Minocycl ine has documented MMP inhibi tory 
activit ies [8-10]. In a model of ischemia in mice, 
minocycline reduced injury in wild-type, but not 
MMP-9 null mice, implicating MMP-9 as a target of 
minocycline activity in that condition[20]. Thus, it was 
reasonable to address whether or not the application 
of minocycline to mice subjected to SCI would result in 
reduced expression or activity of MMPs at lesion sites. 
Our overall results, however, do not support a mode 
of action of minocycline in acute SCI involving MMPs. 
We did not find reduced expression of transcripts 
encoding most MMPs in the spinal cord of mice 
afflicted with SCI and given minocycline. Also, MMP-2 
and -9 protein levels were unaltered in the spinal cord 
of mice administered minocycline. Furthermore, we 
used in situ zymography to determine net proteolytic 
activity in spinal cord sections and we found no 
alterations in minocycline versus vehicle treated 
controls. It is probable that the acute administration of 
minocycline did not result in concentrations that were 
high enough to alter MMP activity and levels.
Despite the lack of effect of minocycline on MMPs, 
the medication did produce neuroprotective effects 
exemplif ied by the NeuN data. Previously we 
have demonstrated that minocycline produces 
robust neuroprotection in this model of spinal cord 
compression in the mouse, significantly decreasing 
lesion size and improving recovery in hindlimb function 
as assessed by the BBB scale in open field testing 
and the inclined plane task[5]. Furthermore, in that 
study, there were indications of white matter sparing 
determined by Bielchowsky silver stain and retrograde 
labeling of brain stem neurons by the fluorogold 
tracer[5]. The current data confirms that there is 
preservation of the gray matter at the level of the impact 
injury as well. While several groups have reported 
improved outcomes from spinal cord injury when 
minocycline is administered[5-7], these studies have not 
comprehensively evaluated the survival of neurons 
throughout the gray matter at the level of injury. Taken 
together, the existing body of research indicates that 
minocycline has a global neuroprotective effect. 
One reason that minocycline is such an attractive 
pharmacological agent for neurological disorders is that 
it has multiple mechanisms of action targeting separate 
pathological processes simultaneously. Besides 
Figure 5: Minocycline treatment reduces the number of cells undergoing apoptotic cell death. Tunel positive cells were counted in sections 
from vehicle and minocycline treated mice harvested at 2 and 5 days post SCI. Cell death was evident 2 days after injury and was still 
ongoing at 5 days. The number of Tunel positive cells counted from the minocycline group was significantly lower than the vehicle group at 
5 days post SCI (Student’s t-test, *P < 0.05, n = 9/group, one longitudinal section containing the central canal per mouse). SCI: spinal cord 
injury
P < 0.05
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reducing inflammatory activity of microglia and T cells[1], 
the over-activation of which contributes to neural cell 
death, minocycline reduces toxicity to oligodendrocytes 
and neurons through potentially direct mechanisms. 
In this regard, minocycline inhibits the activity of 
caspases[21,22] and the release of cytochrome c from 
mitochondria[23], which are both apoptosis-inducing 
events. Minocycline reduces signaling of the p38 
mitogen activated kinase pathway[6,24], and it prevents 
the activation of poly (ADP-ribose) polymerase[25,26], 
actions that contribute to the alleviation of neural cell 
death. This drug has also been shown to decrease 
apoptosis of oligodendrocytes through a mechanism 
involving the inhibition of proNGF production by 
microglia[27]. Minocycline has been reported to reduce 
glutamate excitotoxicity[28,29], to detoxify free radicals 
that contribute to neurotoxicity[30,31] and to inhibit lipid 
peroxidation[32].
A limitation of the present study is that we did not 
per form neurobehavioral studies to accompany 
the histological and MMP results. However, the 
dose regimen employed is identical to that used in 
our previous study[5] that demonstrated behavioral 
recovery by 3 days post-injury in the minocycline 
compared to vehicle group. Another limitation is that 
for the majority of MMPs examined in the current 
study, only gene expression and not protein amount 
or activity was measured. However, protein levels of 
MMPs-2 and 9 were measured using gel zymography, 
and net proteolytic activity for these two molecules 
were examined with in situ zymography. Despite this 
limitation, the transcript expression pattern of MMPs 
provides valuable information in understanding the 
mechanisms by which minocycline may exert its 
effects after SCI.
In conclusion, the novel findings are that minocycline 
confers protection to neurons at the site of SCI, 
and that this does not involve the alteration of most 
MMPs. Given the neurotoxicity that can be inflicted 
by MMPs acutely after SCI, and the apparent lack of 
minocycline effect on most MMPs and TIMPs in this 
study, our results suggest that the combined treatment 
of minocycline and a specific MMP inhibitor may 
result in greater recovery than either treatment alone. 
Nonetheless, even without MMP inhibitory activity 
acutely after SCI, the myriad of mechanisms attributed 
to minocycline as aforementioned would position 
minocycline for further study as a neuroprotective 
medication after SCI in humans. 
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